3D Organoid Drug Screening via Optical Membrane Motion Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pre-clinical models for cancer research face limitations in accurately predicting clinical responses due to the absence of the tumor microenvironment and reliance on incompatible experimental conditions, leading to restricted drug testing and limited predictive biomarkers.
Innovation Solution
Non-destructive methods for quantifying cell viability by culturing cells in a chamber that recapitulates the cancer microenvironment, using optical signals to detect cell membrane motion, and generating multi-parameter models to predict treatment responses and select cancer treatment regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional in vitro assays using cell lines are used, then the assays are scalable, reproducible and inexpensive, but the cell lines are significantly different from their originating tumors and the tumor microenvironment's effects are absent
Solution Approach 1:
The patent uses patient-derived xenograft (PDX) models that copy the actual patient tumor architecture, genetics, and microenvironment in vivo, then validates findings in patient-derived organoids that replicate the tumor structure. This copying approach maintains predictive accuracy while enabling scalable preclinical testing.
Solution Approach 2:
The patent changes the fundamental parameters of the assay system by transitioning from immortalized cell lines to primary patient tumor cells grown in physiologically relevant conditions (3D culture, appropriate stromal cells, immune cells), thereby improving predictive accuracy while maintaining scalability through standardized protocols.
2Reliability
If animal models are used, then more realistic elements such as drug pharmacokinetics and influence of the tumor microenvironment are included, but they require long-term experiments and carry significant financial cost
Solution Approach 1:
The patent extracts the essential tumor microenvironment components (stromal cells, immune cells, extracellular matrix) and recreates them in simplified 3D organoid cultures, retaining the realistic interactions needed for predictive accuracy while eliminating the time and cost constraints of full animal models.
Solution Approach 2:
The patent uses patient-derived organoids as an intermediary system between in vitro cell culture and in vivo animal models. These organoids capture the tumor microenvironment's influence on drug response without requiring the complexity and duration of animal studies, serving as a bridge that accelerates preclinical testing.
3Measurement precision
If early in vitro colony formation assays are used, then the capacity to estimate clinical response is provided, but the cloning efficiency is low (0.001%-0.1%) and the number of drugs and concentrations that can be studied is limited
Solution Approach 1:
The patent segments the drug testing process into multiple parallel 3D organoid cultures, each treated with different drugs and concentrations simultaneously. This segmentation allows comprehensive testing of multiple therapeutic conditions without being constrained by low cloning efficiency in traditional colony assays.
Solution Approach 2:
The patent transitions from 2D colony formation assays to 3D organoid cultures, adding a spatial dimension that increases cloning efficiency and allows higher throughput testing. The 3D architecture better mimics in vivo tumor structure while enabling more samples to be processed in parallel.
4Loss of information
If traditional assays are used, then sensitivity or resistance classification is provided, but no information is provided regarding duration of response and time to relapse
Solution Approach 1:
The patent implements longitudinal monitoring of 3D organoid cultures over extended periods, continuously measuring tumor growth dynamics and drug response. This continuous observation captures the full temporal profile of treatment response, including duration of response and time to relapse, providing comprehensive predictive information beyond binary classification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate prediction of drug responses, progression-free survival, and effective dosing schedules by simulating long-term tumor behavior and overcoming limitations of traditional assays.
Implementation Method 1
capturing a first optical signal from the cells at a first time point; capturing a second optical signal from the cells at a second time point; analyzing the first optical signal and the second optical signal to detect cell membrane motion of the cells
Data Source
AI summary
Disclosed is a method for selecting a cancer treatment regimen for a subject.